Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Payables (2023 - 2025)

Beta Bionics (BBNX) has disclosed Payables for 3 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • Quarterly Payables rose 75.25% to $5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2025, up 75.25% year-over-year, with the annual reading at $5.0 million for FY2025, 75.25% up from the prior year.
  • Payables hit $5.0 million in Q4 2025 for Beta Bionics, up from $4.5 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $5.0 million in Q4 2025 to a low of $1.2 million in Q4 2023.
  • Historically, Payables has averaged $3.4 million across 3 years, with a median of $3.4 million in 2025.
  • Biggest five-year swings in Payables: soared 144.6% in 2024 and later surged 75.25% in 2025.
  • Year by year, Payables stood at $1.2 million in 2023, then soared by 144.6% to $2.9 million in 2024, then skyrocketed by 75.25% to $5.0 million in 2025.
  • Business Quant data shows Payables for BBNX at $5.0 million in Q4 2025, $4.5 million in Q3 2025, and $3.4 million in Q2 2025.